Lead Sponsor

AstraZeneca

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Adults ≥ 18 years at enrollment with diagnosis of NF1 with symptomatic, inoperable PN
•At least one inoperable target PN measurable by volumetric MRI analysis
•Chronic target PN pain score documented for minimum period during screening period
•Stable chronic PN pain medication use at enrollment
•Adequate organ and marrow function

•Confirmed or suspected malignant glioma or MPNST (low grade glioma, including optic glioma not requiring systemic therapy or radiation therapy are exempt from this exclusion)
•History of malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence
•Clinically significant cardiovascular disease, including inherited coronary disease, acute coronary syndrome within 6 months prior to enrollment, uncontrolled angina, symptomatic heart failure, cardiomyopathy, severe valvular heart disease, abnormal LVEF and uncontrolled hypertension
•Ophthalmological findings/conditions including intraocular pressure \> 21 mmHg, RPED/CSR or RVO
•Prior exposure to MEK inhibitors

Related studies

NCT04750928 · Neurofibromatosis 1

NCT05735717 · Hematologic Malignancy, Acute Leukemia, and more

NCT05361811 · Neurofibromatosis 1, Noonan Syndrome, and more

NCT04395495 · RAS Mutation, Neurofibromatosis 1, and more

NCT06262113 · Neurofibromatosis 1

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas